知镜 Cognispect · 医学文献与研究工作台

Low-dose IL-2 therapy in autoimmune diseases: mechanisms, clinical evidence, and future strategies for precision immune regulation.

Fan Z, Zhu W, Yu H.
Clinical reviews in allergy & immunology · 2026-11-03 · PMID 42975756

文献摘要

Low-dose interleukin-2 (LD-IL-2) is being developed as an immune-regulatory therapy across rheumatic and autoimmune diseases, but its biology cannot be reduced to regulatory T-cell (Treg) expansion. IL-2 responses are determined by dose and exposure, receptor abundance and binding kinetics, activation state, tissue distribution, and the balance among JAK-STAT5, PI3K-AKT-mTOR, and RAS-MAPK signaling. CD25-high Tregs have a competitive advantage at low concentrations, yet activated conventional T cells, CD8 + T cells, natural killer cells, follicular T-cell subsets, B-cell compartments, and tissue-resident populations may also be modulated directly or indirectly. We therefore synthesize the field through a cross-disease framework linking receptor pharmacology, signaling thresholds, Treg heterogeneity, epigenetic and metabolic fitness, receptor trafficking, and tissue microenvironments to pharmacodynamic, clinical, and durable responses. Disease-specific evidence is critically compared rather than interpreted as a uniform IL-2-deficiency syndrome: systemic lupus erythematosus combines T-cell IL-2 deficiency with Tfh-B-cell and age-associated B-cell pathology; inflammatory arthritis is constrained by synovial cytokine consumption and tissue access; systemic sclerosis by vascular-fibrotic remodeling; inflammatory myopathy by muscle, skin, lung, and microbiome contexts; and neurological autoimmunity by blood-brain-barrier penetration and compartmentalized inflammation. Randomized evidence supports biological activity and preliminary efficacy in selected settings, whereas many indications remain supported by small, uncontrolled studies. Native LD-IL-2 and engineered agonists also require separate evaluation because altered affinity and half-life can change cellular selectivity, immunogenicity, biodistribution, and the risk of chronic receptor overstimulation. We conclude that development should prioritize disease-specific dose-exposure relationships, functional and tissue-resolved biomarkers, rigorous clinical endpoints, and long-term surveillance. This framework positions IL-2 therapy as context-dependent network modulation rather than universal restoration of immune tolerance.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。